DLBCL leads the highest level of PD-L1 expression in B-cell NHLs (Yang & Hu, 2019), but PD-1/PD-L1 mAbs are only utilized as a later-line therapeutic option for DLBCL, with insufficient evidence to guide their clinical application. Here, CD274 is linked to B-cell non-Hodgkin lymphoma.